fragment-based screening and fragment-based drug design

Fragment-Based Screening and Drug Discovery Services

Fragment screening and fragment-based drug discovery (FBDD) services platform at SARomics Biostructures is based on our unique and proprietary weak affinity chromatography technology (WAC™ ). Our experts together with the client and depending on the project, will design the best hit identification and hit-to-lead design strategy. Our expertise in computational chemistry, fragment-screening and structure-based drug discovery is applied to ensure the most optimal hit identification and expansion, fragment-to-hit and hit-to-lead optimization process. The hit expansion and subsequent optimization programs are run in close collaboration with our partner Red Glead Discovery.

Our FBDD platform provides full-range discovery services

WAC™ screening technology

Our proprietary WAC™ (weak affinity chromatography) screening technology allows simultaneous identification of weak binders (mM-μM) in complex mixtures, as well as Kd calculation. Detection by LC-MS. For details please download a pdf

Other biophysical screening methods

Our screening platform also uses a range of biophysical screening methods, which include thermal-shift assay, isothermal titration calorimetry (ITC), NMR spectroscopy and X-ray crystallography

Fragment library

Proprietary library design for easy hit expansion. Please enquire for details.

Structural biology

Highly efficient structural biology platform and extensive experience in the use of structural data in hit expansion and lead optimization

Computational chemistry

Extensive experience in hit expansion, pharmacophore- and shape-based virtual screening, scaffold hopping, QSAR analysis and optimization

Medicinal chemistry

Through our collaboration with Red Glead we offer expertise in lead optimization, biological characterization, medicinal chemistry and ADME